开拓药业-B(09939.HK):GT20029凝胶治疗痤疮中国II期临床试验达到主要终点

智通财经
Aug 12
【开拓药业-B(09939.HK):GT20029凝胶治疗痤疮中国II期临床试验达到主要终点】智通财经APP讯,开拓药业-B(09939.HK)发布公告,该公司自主研发的新型靶向雄激素受体(AR)的蛋白降解嵌合体(PROTAC)化合物GT20029治疗痤疮的该项II期临床试验读出顶线数据。数据显示,该项II期临床试验成功达到主要研究终点,结果具有统计学显著性及临床意义,且有效性、安全性和药代动力学特征均表现出色,并确定III期临床试验的推荐剂量为0.5%。详细的顶线结果资料未来预计在学术期刊或学术会议上予以公布。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10